Shopping Cart

Your shopping cart is currently empty

EGFR/COX_2-IN_3

Name: EGFR/COX_2-IN_3
Brand: TargetMol
SKU: T212904
Price: 195 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: EGFR/COX_2-IN_3) Copy Product Info

🥰Excellent

Synonyms: EGFR/COX_2-IN_3

Catalog No. T212904 Copy Product Info

Purity: 99.96%

🥰Excellent

EGFR/COX-2-IN-3 is a highly selective dual-target inhibitor of EGFR and COX-2, with IC50 values of 0.098 μM and 0.05 μM for the two targets respectively. Pharmacological prediction Results: show that it possesses good oral bioavailability and blood-brain barrier penetration ability. Meanwhile, it exhibits significant analgesic effects and anti-glioblastoma pharmacological activity, and can be applied to mechanism and efficacy research of glioblastoma and other tumors.

Cas No. 3121638-16-9

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
1 mg	$195	-	In Stock
5 mg	$483	-	In Stock
10 mg	$691	-	In Stock
25 mg	$1,080	-	In Stock
50 mg	$1,490	-	In Stock
100 mg	$1,960	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.96%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	EGFR/COX-2-IN-3 is a highly selective dual-target inhibitor of EGFR and COX-2, with IC50 values of 0.098 μM and 0.05 μM for the two targets respectively. Pharmacological prediction Results: show that it possesses good oral bioavailability and blood-brain barrier penetration ability. Meanwhile, it exhibits significant analgesic effects and anti-glioblastoma pharmacological activity, and can be applied to mechanism and efficacy research of glioblastoma and other tumors.
In vitro	Methods: An in vitro cell proliferation inhibition assay was used to detect the proliferative inhibitory effect of EGFR/COX-2-IN-3 on human glioma U-251 and SNB-75 cells, and the half-maximal inhibitory concentration (IC₅₀) was determined. Results: EGFR/COX-2-IN-3 exhibited significant cytotoxicity and proliferation inhibitory activity against both U-251 and SNB-75 glioma cells, with IC₅₀ values of 8.8 μM and 2.6 μM, respectively [1].
In vivo	Methods: The analgesic activity of EGFR/COX-2-IN-3 was evaluated using the mouse hot plate test, with celecoxib set as the control for comparison. Results: EGFR/COX-2-IN-3 exhibited evident analgesic activity in the mouse hot plate test, with an AUC value of 37.83, which was superior to celecoxib [1].
Synonyms	EGFR/COX_2-IN_3

Chemical Properties

Molecular Weight	375.47
Formula	C₂₂H₂₅N₅O
Cas No.	3121638-16-9
Smiles	O=C(CN1CCN(C)CC1)NC2=CC(C3=CC=CC=C3)=NN2C4=CC=CC=C4
Relative Density.	no data available

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Related Tags: EGFR/COX_2-IN_3 chemical structure | EGFR/COX_2-IN_3 in vivo | EGFR/COX_2-IN_3 in vitro | EGFR/COX_2-IN_3 formula | EGFR/COX_2-IN_3 molecular weight